Statins in lymphangioleiomyomatosis

Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling

Elena N. Atochina-Vasserman, Dmitry A. Goncharov, Alla V. Volgina, Megan Milavec, Melane L. James, Vera P. Krymskaya

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Mutations of the tumor suppressor genes tuberous sclerosis complex (TSC)1 andTSC2 causepulmonarylymphangioleiomyomatosis (LAM) and tuberous sclerosis (TS). Current rapamycin-based therapies for TS and LAM have a predominantly cytostatic effect, and disease progression resumes with therapy cessation. Evidence of RhoA GTPase activation in LAM-derived and human TSC2-null cells suggests that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor statins can be used as potential adjuvant agents. The goal of this studywas to determinewhich statin (simvastatin or atorvastatin) is more effective in suppressing TSC2-null cell growth and signaling. Simvastatin, but not atorvastatin, showed a concentrationdependent (0.5-10 μM) inhibitory effect on mouse TSC2-null and human LAM-derived cell growth. Treatment with 10 μM simvastatin induced dramatic disruption of TSC2-null cell monolayer and cell rounding; in contrast, few changes were observed in cells treated with the same concentration of atorvastatin. Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells. Simvastatin, but not atorvastatin, inhibitedthe activity of prosurvival serine-threonine kinase Akt and induced marked up-regulation of cleaved caspase-3, a marker of cell apoptosis. Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Thus, our data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null cells compared with atorvastatin. These findings have translational significance for combinatorial therapeutic strategies of simvastatin to inhibit TSC2- null cell survival in TS and LAM.

Original languageEnglish
Pages (from-to)704-709
Number of pages6
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume49
Issue number5
DOIs
Publication statusPublished - Nov 2013
Externally publishedYes

Fingerprint

Lymphangioleiomyomatosis
Cell signaling
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Null Lymphocytes
Tuberous Sclerosis
Simvastatin
Cell growth
Growth
Sirolimus
Atorvastatin Calcium
Tuberous Sclerosis 2
Protein-Serine-Threonine Kinases
GTP Phosphohydrolases
Cytostatic Agents
Tumor Suppressor Genes
Caspase 3
Disease Progression
Tumors
Monolayers
Cell Survival

Keywords

  • Apoptosis
  • LAM
  • MTOR
  • TSC
  • TSC2

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Statins in lymphangioleiomyomatosis : Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. / Atochina-Vasserman, Elena N.; Goncharov, Dmitry A.; Volgina, Alla V.; Milavec, Megan; James, Melane L.; Krymskaya, Vera P.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 49, No. 5, 11.2013, p. 704-709.

Research output: Contribution to journalArticle

@article{841605871c1243dcb45f74eb8693aad8,
title = "Statins in lymphangioleiomyomatosis: Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling",
abstract = "Mutations of the tumor suppressor genes tuberous sclerosis complex (TSC)1 andTSC2 causepulmonarylymphangioleiomyomatosis (LAM) and tuberous sclerosis (TS). Current rapamycin-based therapies for TS and LAM have a predominantly cytostatic effect, and disease progression resumes with therapy cessation. Evidence of RhoA GTPase activation in LAM-derived and human TSC2-null cells suggests that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor statins can be used as potential adjuvant agents. The goal of this studywas to determinewhich statin (simvastatin or atorvastatin) is more effective in suppressing TSC2-null cell growth and signaling. Simvastatin, but not atorvastatin, showed a concentrationdependent (0.5-10 μM) inhibitory effect on mouse TSC2-null and human LAM-derived cell growth. Treatment with 10 μM simvastatin induced dramatic disruption of TSC2-null cell monolayer and cell rounding; in contrast, few changes were observed in cells treated with the same concentration of atorvastatin. Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells. Simvastatin, but not atorvastatin, inhibitedthe activity of prosurvival serine-threonine kinase Akt and induced marked up-regulation of cleaved caspase-3, a marker of cell apoptosis. Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Thus, our data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null cells compared with atorvastatin. These findings have translational significance for combinatorial therapeutic strategies of simvastatin to inhibit TSC2- null cell survival in TS and LAM.",
keywords = "Apoptosis, LAM, MTOR, TSC, TSC2",
author = "Atochina-Vasserman, {Elena N.} and Goncharov, {Dmitry A.} and Volgina, {Alla V.} and Megan Milavec and James, {Melane L.} and Krymskaya, {Vera P.}",
year = "2013",
month = "11",
doi = "10.1165/rcmb.2013-0203RC",
language = "English",
volume = "49",
pages = "704--709",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Statins in lymphangioleiomyomatosis

T2 - Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling

AU - Atochina-Vasserman, Elena N.

AU - Goncharov, Dmitry A.

AU - Volgina, Alla V.

AU - Milavec, Megan

AU - James, Melane L.

AU - Krymskaya, Vera P.

PY - 2013/11

Y1 - 2013/11

N2 - Mutations of the tumor suppressor genes tuberous sclerosis complex (TSC)1 andTSC2 causepulmonarylymphangioleiomyomatosis (LAM) and tuberous sclerosis (TS). Current rapamycin-based therapies for TS and LAM have a predominantly cytostatic effect, and disease progression resumes with therapy cessation. Evidence of RhoA GTPase activation in LAM-derived and human TSC2-null cells suggests that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor statins can be used as potential adjuvant agents. The goal of this studywas to determinewhich statin (simvastatin or atorvastatin) is more effective in suppressing TSC2-null cell growth and signaling. Simvastatin, but not atorvastatin, showed a concentrationdependent (0.5-10 μM) inhibitory effect on mouse TSC2-null and human LAM-derived cell growth. Treatment with 10 μM simvastatin induced dramatic disruption of TSC2-null cell monolayer and cell rounding; in contrast, few changes were observed in cells treated with the same concentration of atorvastatin. Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells. Simvastatin, but not atorvastatin, inhibitedthe activity of prosurvival serine-threonine kinase Akt and induced marked up-regulation of cleaved caspase-3, a marker of cell apoptosis. Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Thus, our data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null cells compared with atorvastatin. These findings have translational significance for combinatorial therapeutic strategies of simvastatin to inhibit TSC2- null cell survival in TS and LAM.

AB - Mutations of the tumor suppressor genes tuberous sclerosis complex (TSC)1 andTSC2 causepulmonarylymphangioleiomyomatosis (LAM) and tuberous sclerosis (TS). Current rapamycin-based therapies for TS and LAM have a predominantly cytostatic effect, and disease progression resumes with therapy cessation. Evidence of RhoA GTPase activation in LAM-derived and human TSC2-null cells suggests that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor statins can be used as potential adjuvant agents. The goal of this studywas to determinewhich statin (simvastatin or atorvastatin) is more effective in suppressing TSC2-null cell growth and signaling. Simvastatin, but not atorvastatin, showed a concentrationdependent (0.5-10 μM) inhibitory effect on mouse TSC2-null and human LAM-derived cell growth. Treatment with 10 μM simvastatin induced dramatic disruption of TSC2-null cell monolayer and cell rounding; in contrast, few changes were observed in cells treated with the same concentration of atorvastatin. Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells. Simvastatin, but not atorvastatin, inhibitedthe activity of prosurvival serine-threonine kinase Akt and induced marked up-regulation of cleaved caspase-3, a marker of cell apoptosis. Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Thus, our data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null cells compared with atorvastatin. These findings have translational significance for combinatorial therapeutic strategies of simvastatin to inhibit TSC2- null cell survival in TS and LAM.

KW - Apoptosis

KW - LAM

KW - MTOR

KW - TSC

KW - TSC2

UR - http://www.scopus.com/inward/record.url?scp=84887052370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887052370&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2013-0203RC

DO - 10.1165/rcmb.2013-0203RC

M3 - Article

VL - 49

SP - 704

EP - 709

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 5

ER -